Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Current Leases: 2023-2025

  • China SXT Pharmaceuticals' Current Leases fell 0.11% to -$34,776 in Q3 2025 from the same period last year, while for Sep 2025 it was -$34,776, marking a year-over-year decrease of 0.11%. This contributed to the annual value of $61,229 for FY2025, which is 5.01% up from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Current Leases stood at -$34,776, which was down 156.80% from $61,229 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Current Leases ranged from a high of $61,229 in Q1 2025 and a low of -$35,098 during Q3 2023.
  • Its 3-year average for Current Leases is $12,169, with a median of $11,675 in 2023.
  • Over the last 5 years, China SXT Pharmaceuticals' Current Leases had its largest YoY gain of 5.01% in 2025, and its largest YoY loss of 0.11% in 2025.
  • Over the past 3 years, China SXT Pharmaceuticals' Current Leases (Quarterly) stood at -$35,098 in 2023, then grew by 1.02% to -$34,739 in 2024, then fell by 0.11% to -$34,776 in 2025.
  • Its Current Leases stands at -$34,776 for Q3 2025, versus $61,229 for Q1 2025 and -$34,739 for Q3 2024.